Results of the Super CitriMax® human clinical study conducted by researchers at Georgetown University Medical Center and Andhra University in India, have been published in Nutrition Research (24(1): 45-58, 2004). Super CitriMax, a patent-pending form of (-)hydroxycitric acid (HCA), is a proprietary, ephedra-free weight loss ingredient developed by InterHealth Nutraceuticals. The new study explored the use of higher doses and a more bioavailable form of HCA bound to calcium and potassium. According to the company, patients in the study not only experienced significant weight loss, but increased fat burning, lowered cholesterol, increased beneficial HDL cholesterol and decreased body mass index (BMI), an indicator of obesity health risk. The eight-week, randomized, double-blind, placebo-controlled human clinical trial also revealed that Super CitriMax significantly increased serum serotonin levels and lowered serum leptin levels, a biomarker of the gene that regulates obesity.